IVVD

Insider Trades

Name	Value	Action	Price	Current Price
Andersen JillChief Legal Officer, Secretary $55k34.9k shares SellFeb 18, 2026 $1.58 --
Allen Robert D. IIIChief Scientific Officer $31k19.4k shares SellFeb 18, 2026 $1.58 --
Duke William E.Chief Financial Officer $33k21k shares SellFeb 18, 2026 $1.58 --
Green JulieChief Human Resources Officer $33k21k shares SellFeb 18, 2026 $1.58 --
Lee Timothy EdwardChief Commercial Officer $33k21k shares SellFeb 18, 2026 $1.58 --
Andersen JillChief Legal Officer, Secretary $50k32.8k shares SellFeb 17, 2026 $1.54 --

News

globenewswire.comInvivyd Announces Completion of Enrollment in Phase 3 LIBERTY Trial Evaluating VYD2311 Antibody Versus mRNA COVID-19 Vaccineglobenewswire.comJun 16

proactiveinvestors.comInvivyd doses first participants in Phase 3 COVID-19 trialproactiveinvestors.comJun 9

globenewswire.comInvivyd Announces First Participants Dosed in LIBERTY, a Phase 3 Clinical Trial to Evaluate the Safety and Tolerability of VYD2311 Antibody Versus mRNA COVID Vaccine and to Characterize the Safety and Immunology of Antibody and mRNA Vaccine Co-Administrationglobenewswire.comJun 9

globenewswire.comInvivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.comJun 3

Trade IVVD

About Invivyd, Inc.

Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development phase, operates within the United States, specializing in the discovery, progression, and marketing of antibody-derived solutions for infectious diseases. The company's leading drug candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical investigation for both the management and prevention of coronavirus disease. Adagio Therapeutics maintains collaborative agreements with Adimab, LLC to facilitate the identification and enhancement of its exclusive antibodies. Furthermore, it partners with the Scripps Research Institute to conduct studies aimed at uncovering potential vaccine solutions for the prophylaxis, detection, or therapy of influenza or beta coronaviruses. Incorporated in 2020, the company's base of operations is in Waltham, Massachusetts.

CEO: William E. Duke Jr.
IPO Date: Aug 6, 2021

Market Data

Open: $0.9401
High: $1.01
Low: $0.902
Volume: 14.1M
Avg Volume: 4M
52W High: $3.07
52W Low: $0.483

Valuation

Market Cap: $129M
Enterprise Value: $-47M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-58M
Revenue: $53M
Net Income: $-52M
Cash: $227M
Debt: $2.5M

Events

EarningsAug 13

EPS est. -0.15